Clinical Cancer Research, Vol 3, Issue 6 911-921, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase

AL Jackman, R Kimbell, GW Aherne, L Brunton, G Jansen, TC Stephens, MN Smith, JM Wardleworth and FT Boyle
The Cancer Research Campaign Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG United Kingdom. annj@icr.ac.uk

ZD9331 is a drug that was developed from a potent class of water-soluble, C7-methyl-substituted, quinazoline-based inhibitors of thymidylate synthase (TS) that are transported into cells via a saturable, carrier-mediated system (reduced folate carrier, or RFC) but are not substrates for folylpolyglutamate synthetase. ZD9331 is the gamma-tetrazole analogue of 2-desamino-2, 7-dimethyl-N10-propargyl-2'fluoro-5,8-dideaza folate (ZM214888), with a TS Ki of approximately 0.4 nM. ZD9331 exhibits potent growth inhibitory and cytotoxic activity; e.g., IC50 for the inhibition of human W1L2 lymphoblastoid cell line was 7 nM. The addition of thymidine to the culture medium increased the IC50 in W1L2 cells >10, 000-fold, demonstrating the high specificity of the drug for TS. ZD9331 is transported into cells predominantly via the RFC. Accordingly, it competes with methotrexate (MTX) and folinic acid for cellular uptake and has reduced activity against two cell lines with low expression of the RFC (L1210:1565 and CEM/MTX). In addition, a cell line with acquired resistance to ZD9331 displays reduced uptake of both ZD9331 and MTX. A mouse cell line (L1210:RD1694), with acquired resistance to ZD1694 due to reduced folylpolyglutamate synthetase activity, was not significantly cross-resistant to ZD9331. The flux through TS, as measured by 3H release from 5-[3H]deoxyuridine, was rapidly inhibited when cells were incubated with ZD9331. However, because ZD9331 cannot form polyglutamates, TS activity recovered rapidly once cells were placed in drug-free medium. The minimum curative dose of ZD9331 in the i.m. L5178Y TK-/- tumor model was approximately 3 mg/kg when given by 24-h continuous infusion, and it was 25-50 mg/kg when given by a single i.p. or i.v. injection. ZD9331 had antitumor activity against the L5178Y TK+/- tumor when administered by 7-day continuous infusion; growth delays of more than 5 days (and some cures) were seen at doses of 25-50 mg/kg/day. At higher doses, significant weight loss (gastrointestinal toxicity) and myelosuppression (neutropenia and thrombocytopenia) were observed, suggesting that these may be dose-limiting toxicities in the Phase I clinical studies.

This article has been cited by other articles:

				R. G. Pillai, M. Forster, M. Perumal, F. Mitchell, J. Leyton, F. I. Aibgirhio, O. Golovko, A. L. Jackman, and E. O. Aboagye Imaging Pharmacodynamics of the {alpha}-Folate Receptor-Targeted Thymidylate Synthase Inhibitor BGC 945 Cancer Res., May 15, 2008; 68(10): 3827 - 3834. [Abstract] [Full Text] [PDF]

				A. L Jackman Exploiting Folate Pathways and Transporters for the Management and Treatment of Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 101 - 108. [Abstract] [Full Text] [PDF]

				J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095. [Abstract] [Full Text] [PDF]

				D. D. Gibbs, D. S. Theti, N. Wood, M. Green, F. Raynaud, M. Valenti, M. D. Forster, F. Mitchell, V. Bavetsias, E. Henderson, et al. BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to {alpha}-Folate Receptor-Overexpressing Tumors Cancer Res., December 15, 2005; 65(24): 11721 - 11728. [Abstract] [Full Text] [PDF]

				D. S. Theti and A. L. Jackman The Role of {alpha}-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs Clin. Cancer Res., February 1, 2004; 10(3): 1080 - 1089. [Abstract] [Full Text] [PDF]

				L. Rothem, M. Stark, Y. Kaufman, L. Mayo, and Y. G. Assaraf Reduced Folate Carrier Gene Silencing in Multiple Antifolate-resistant Tumor Cell Lines Is Due to a Simultaneous Loss of Function of Multiple Transcription Factors but Not Promoter Methylation J. Biol. Chem., January 2, 2004; 279(1): 374 - 384. [Abstract] [Full Text] [PDF]

				J. Geller, I. Petak, K. S. Szucs, K. Nagy, D. M. Tillman, and J. A. Houghton Interferon-{gamma}-Induced Sensitization of Colon Carcinomas to ZD9331 Targets Caspases, Downstream of Fas, Independent of Mitochondrial Signaling and the Inhibitor of Apoptosis Survivin Clin. Cancer Res., December 15, 2003; 9(17): 6504 - 6515. [Abstract] [Full Text] [PDF]

				D. S. Theti, V. Bavetsias, L. A. Skelton, J. Titley, D. Gibbs, G. Jansen, and A. L. Jackman Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the {alpha}-Isoform of the Folate Receptor Cancer Res., July 1, 2003; 63(13): 3612 - 3618. [Abstract] [Full Text] [PDF]

				C. Rees, P. Beale, J. M. Trigo, F. Mitchell, A. Jackman, R. Smith, E. Douglass, and I. Judson Phase I Trial of ZD9331, a Nonpolyglutamatable Thymidylate Synthase Inhibitor, Given as a 5-Day Continuous Infusion to Patients with Refractory Solid Malignancies Clin. Cancer Res., June 1, 2003; 9(6): 2049 - 2055. [Abstract] [Full Text] [PDF]

				P. Wells, E. Aboagye, R. N. Gunn, S. Osman, A. V. Boddy, G. A. Taylor, I. Rafi, A. N. Hughes, A. H. Calvert, P. M. Price, et al. 2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337 J Natl Cancer Inst, May 7, 2003; 95(9): 675 - 682. [Abstract] [Full Text] [PDF]

				M. B. Sawyer, M. J. Ratain, D. Bertucci, R. P. Smith, R. L. Schilsky, N. J. Vogelzang, K. Shulman, E. C. Douglass, and G. F. Fleming Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days J. Clin. Oncol., May 1, 2003; 21(9): 1859 - 1865. [Abstract] [Full Text] [PDF]

				R. Plummer, C. Rees, A. Hughes, P. Beale, M. Highley, J. Trigo, S. Gokul, I. Judson, H. Calvert, A. Jackman, et al. A Phase I Trial of ZD9331, a Water-Soluble, Nonpolyglutamatable, Thymidylate Synthase Inhibitor Clin. Cancer Res., April 1, 2003; 9(4): 1313 - 1322. [Abstract] [Full Text] [PDF]

				L. Rothem, A. Aronheim, and Y. G. Assaraf Alterations in the Expression of Transcription Factors and the Reduced Folate Carrier as a Novel Mechanism of Antifolate Resistance in Human Leukemia Cells J. Biol. Chem., March 7, 2003; 278(11): 8935 - 8941. [Abstract] [Full Text] [PDF]

				D. B. Longley, J. Boyer, W. L. Allen, T. Latif, P. R. Ferguson, P. J. Maxwell, U. McDermott, M. Lynch, D. P. Harkin, and P. G. Johnston The Role of Thymidylate Synthase Induction in Modulating p53-regulated Gene Expression in Response to 5-Fluorouracil and Antifolates Cancer Res., May 1, 2002; 62(9): 2644 - 2649. [Abstract] [Full Text] [PDF]

				M. J.A. de Jonge, C. J.A. Punt, A. Sparreboom, A. S.T. Planting, M.E.W.J. Peters, J. van de Schraaf, A. Jackman, R. Smith, P. H.M. de Mulder, and J. Verweij Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors J. Clin. Oncol., April 1, 2002; 20(7): 1923 - 1931. [Abstract] [Full Text] [PDF]

				H. E. R. Ford, F. Mitchell, D. Cunningham, D. C. Farrugia, M. E. Hill, C. Rees, A. H. Calvert, I. R. Judson, and A. L. Jackman Patterns of Elevation of Plasma 2'-Deoxyuridine, a Surrogate Marker of Thymidylate Synthase (TS) Inhibition, after Administration of Two Different Schedules of 5-Fluorouracil and the Specific TS Inhibitors Raltitrexed (Tomudex) and ZD9331 Clin. Cancer Res., January 1, 2002; 8(1): 103 - 109. [Abstract] [Full Text] [PDF]

				D. B. Longley, P. R. Ferguson, J. Boyer, T. Latif, M. Lynch, P. Maxwell, D. P. Harkin, and P. G. Johnston Characterization of a Thymidylate Synthase (TS)-inducible Cell Line: A Model System for Studying Sensitivity to TS- and non-TS-targeted Chemotherapies Clin. Cancer Res., November 1, 2001; 7(11): 3533 - 3539. [Abstract] [Full Text] [PDF]

				G. W. Aherne, A. Hardcastle, E. Ward, D. Dobinson, T. Crompton, M. Valenti, L. Brunton, and A. L. Jackman Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules Clin. Cancer Res., September 1, 2001; 7(9): 2923 - 2930. [Abstract] [Full Text] [PDF]

				P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, A. H. Calvert, D. R. Newell, and N. J. Curtin In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity Clin. Cancer Res., July 1, 2001; 7(7): 2105 - 2113. [Abstract] [Full Text] [PDF]

				C. L. van der Wilt, H. H. J. Backus, K. Smid, L. Comijn, G. Veerman, D. Wouters, D. A. Voorn, D. G. Priest, M. A. Bunni, F. Mitchell, et al. Modulation of Both Endogenous Folates and Thymidine Enhance the Therapeutic Efficacy of Thymidylate Synthase Inhibitors Cancer Res., May 1, 2001; 61(9): 3675 - 3681. [Abstract] [Full Text]

				B. C. Goh, M. J. Ratain, D. Bertucci, R. Smith, S. Mani, N. J. Vogelzang, R. L. Schilsky, M. Hutchison, M. Smith, S. Averbuch, et al. Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations J. Clin. Oncol., March 1, 2001; 19(5): 1476 - 1484. [Abstract] [Full Text] [PDF]

				S. J. Welsh, J. Titley, L. Brunton, M. Valenti, P. Monaghan, A. L. Jackman, and G. W. Aherne Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues Clin. Cancer Res., June 1, 2000; 6(6): 2538 - 2546. [Abstract] [Full Text]

				M. G. Rots, R. Pieters, G. J. Peters, C. H. van Zantwijk, R. Mauritz, P. Noordhuis, J. C. Willey, K. Hahlen, U. Creutzig, G. Janka-Schaub, et al. Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates Blood, November 1, 1999; 94(9): 3121 - 3128. [Abstract] [Full Text] [PDF]

				G. Jansen, H. Barr, I. Kathmann, M. A. Bunni, D. G. Priest, P. Noordhuis, G. J. Peters, and Y. G. Assaraf Multiple Mechanisms of Resistance to Polyglutamatable and Lipophilic Antifolates in Mammalian Cells: Role of Increased Folylpolyglutamylation, Expanded Folate Pools, and Intralysosomal Drug Sequestration Mol. Pharmacol., April 1, 1999; 55(4): 761 - 769. [Abstract] [Full Text]

				G. Jansen, R. Mauritz, S. Drori, H. Sprecher, I. Kathmann, M. Bunni, D. G. Priest, P. Noordhuis, J. H. Schornagel, H. M. Pinedo, et al. A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance J. Biol. Chem., November 13, 1998; 273(46): 30189 - 30198. [Abstract] [Full Text] [PDF]

				R. Zhao, S. Titus, F. Gao, R. G. Moran, and I. D. Goldman Molecular Analysis of Murine Leukemia Cell Lines Resistant to 5,10-Dideazatetrahydrofolate Identifies Several Amino Acids Critical to the Function of Folylpolyglutamate Synthetase J. Biol. Chem., August 18, 2000; 275(34): 26599 - 26606. [Abstract] [Full Text] [PDF]